Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease.

Derer S, Till A, Haesler R, Sina C, Grabe N, Jung S, Nikolaus S, Kuehbacher T, Groetzinger J, Rose-John S, Rosenstiel PC, Schreiber S.

Gut. 2013 Mar;62(3):376-86. doi: 10.1136/gutjnl-2011-300384. Epub 2012 Apr 25.

PMID:
22535372
[PubMed - indexed for MEDLINE]
2.

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF.

Gastroenterology. 2011 Dec;141(6):2026-38. doi: 10.1053/j.gastro.2011.08.032. Epub 2011 Aug 27.

PMID:
21875498
[PubMed - indexed for MEDLINE]
3.

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.

Bourne T, Fossati G, Nesbitt A.

BioDrugs. 2008;22(5):331-7. Review.

PMID:
18778114
[PubMed - indexed for MEDLINE]
4.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T.

Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.

PMID:
17636564
[PubMed - indexed for MEDLINE]
5.

Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective.

Heathfield SK, Parker B, Zeef LA, Bruce IN, Alexander MY.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):225-33. Epub 2012 Dec 13.

PMID:
23295110
[PubMed - indexed for MEDLINE]
6.

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T.

Inflamm Bowel Dis. 2013 May;19(6):1224-31. doi: 10.1097/MIB.0b013e318280b169.

PMID:
23619715
[PubMed - indexed for MEDLINE]
7.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.

Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2. Review. Erratum in: Am J Gastroenterol. 2011 Feb;106(2):375. Watermayer, G [corrected to Watermeyer, G].

PMID:
21045814
[PubMed - indexed for MEDLINE]
8.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
[PubMed - indexed for MEDLINE]
9.

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.

Smith LS, Nelson M, Dolder CR.

Ann Pharmacother. 2010 Feb;44(2):333-42. doi: 10.1345/aph.1M314. Epub 2010 Jan 5. Review.

PMID:
20118143
[PubMed - indexed for MEDLINE]
10.

Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.

Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, Silver J.

Inflamm Bowel Dis. 2004 Nov;10(6):801-10.

PMID:
15626899
[PubMed - indexed for MEDLINE]
11.

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357.

PMID:
17634459
[PubMed - indexed for MEDLINE]
Free Article
12.

Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.

Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW.

Gastroenterology. 2011 Jan;140(1):221-30. doi: 10.1053/j.gastro.2010.10.008. Epub 2010 Oct 16.

PMID:
20955706
[PubMed - indexed for MEDLINE]
13.

Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R.

Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. Review.

PMID:
23620660
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127.

PMID:
20014021
[PubMed - indexed for MEDLINE]
15.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
[PubMed - indexed for MEDLINE]
16.

Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).

Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2012 Aug;18(8):1523-30. doi: 10.1002/ibd.21888. Epub 2011 Oct 10.

PMID:
21987429
[PubMed - indexed for MEDLINE]
17.

Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.

Liu C, Xia X, Wu W, Wu R, Tang M, Chen T, Xu F, Cong Y, Xu X, Liu Z.

Clin Exp Immunol. 2013 Jul;173(1):102-11. doi: 10.1111/cei.12084.

PMID:
23607532
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.

Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.

Aliment Pharmacol Ther. 2010 Aug;32(3):384-93. doi: 10.1111/j.1365-2036.2010.04360.x. Epub 2010 May 18.

PMID:
20491747
[PubMed - indexed for MEDLINE]
19.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.

Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF.

Am J Gastroenterol. 2011 Feb;106(2):214-23; quiz 224. doi: 10.1038/ajg.2010.464. Epub 2010 Dec 14. Review.

PMID:
21157441
[PubMed - indexed for MEDLINE]
20.

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T.

Gastroenterology. 2001 Nov;121(5):1145-57.

PMID:
11677207
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk